U.S. FDA advisory meetings through March 31

**CANCELLED**

ONCOLOGIC DRUGS ADVISORY COMMITTEE

DATE: Feb. 9, 0800/1300

LOCATION: FDA White Oak Campus, Building 31, 10903 New Hampshire Ave., Silver Spring, Md.

CONTACT: Nicole Vesely, 301-796-9001

The committee will discuss a biologics license application for Yervoy (ipilimumab), submitted by Bristol-Myers Squibb Co. The proposed use for this product is for the treatment of advanced melanoma in patients who have received prior therapy.

Note: The FDA said in a notice Dec. 23: "This meeting has been cancelled because the issues for which FDA was seeking the scientific input of the committee have been resolved."

PULMONARY-ALLERGY DRUGS ADVISORY COMMITTEE

DATE: March 8, 0800/1300